Company: HURA
Filing Date: 2025-05-23
Form Type: 424B3
Source: 0001193125-25-125499
Chunk: 543

Company: TuHURA Biosciences, Inc./NV
Filing Date: 2025-05-23
Form: 424B3
Chunk 543
---
ibb Company (“BMS”). See Figure 7 below for more information on competitive products in development. Kineta is developing a VISTA blocking immunotherapy that is designed to be differentiated from competitive products by the following:

| • |     | Engineered IgG1 mAb that binds to a unique epitope |

| • |     | Binding at physiologic and acidic pH in the TME (See Figure 8) |

| • |     | Demonstrated single agent tumor growth inhibition as a monotherapy and in combination with PD-1 inhibitors (See Figure 6) |

| • |     | Well-tolerated with no CRS-associated cytokine release or neurotoxicity 
 (See Figure 9)                                                          |

Figure 7.KVA12123: Differentiated VISTA blocking immunotherapy Other discovery stage programs: Apexigen and Five Prime Therapeutics/BMS. Empty cells indicate no public data available Kineta believes that KVA12123 may be differentiated as the only antibody in its class with strong single-agent tumor growth inhibition in the absence of cytokine-mediate toxicity. 352

Figure 8.KVA12123 binds at physiologic and acidic pH

Source: Kineta data

Figure 9.KVA12123: No CRS-associated cytokine release seen in preclinical models in NHP
toxicology and in human whole blood studies

Source: Kineta data

Clinical rationale for KVA12123

Kineta is developing KVA12123 in large clinical and commercial indications where existing CPIs perform poorly, there is a high unmet medical
need and VISTA expression in the TME is high. Clinical applications for KVA12123 are primarily focused on solid tumors with high levels of VISTA expression. KVA12123 may be an effective immunotherapy for many types of cancer, including NSCLC, CRC,
OC, RCC and HNSCC and other “cold” difficult-to-treat solid tumors. The lead commercial and clinical indications for KVA12123 are NSCLC, CRC and OC based on
the following clinical rationale.

353

NSCLC is the leading cause of cancer-related mortality in the United States with more than 200,000 newly diagnosed cases each year. NSCLC
accounts for about 85% of all diagnosed cases, and about 70% of newly diagnosed NSCLC is already locally advanced or metastatic. For NSCLC that has spread regionally, five-year relative survival rates are 35%. For NSCLC that